IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.248
AS - Asia 13.856
EU - Europa 10.084
SA - Sud America 1.800
AF - Africa 363
OC - Oceania 39
Continente sconosciuto - Info sul continente non disponibili 34
Totale 43.424
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.861
CN - Cina 6.962
SG - Singapore 2.866
IE - Irlanda 2.213
HK - Hong Kong 1.688
UA - Ucraina 1.569
BR - Brasile 1.342
FI - Finlandia 1.177
DE - Germania 1.135
VN - Vietnam 1.090
RU - Federazione Russa 898
SE - Svezia 752
IT - Italia 744
FR - Francia 678
GB - Regno Unito 495
IN - India 266
CA - Canada 192
BD - Bangladesh 174
AR - Argentina 167
ZA - Sudafrica 133
MX - Messico 119
IQ - Iraq 98
PK - Pakistan 87
JP - Giappone 78
TR - Turchia 77
NL - Olanda 75
CO - Colombia 65
PL - Polonia 60
ID - Indonesia 58
SA - Arabia Saudita 53
EC - Ecuador 52
VE - Venezuela 51
UZ - Uzbekistan 48
ES - Italia 47
AT - Austria 46
MA - Marocco 40
CL - Cile 37
BE - Belgio 36
AU - Australia 33
KE - Kenya 32
PH - Filippine 30
IR - Iran 29
MY - Malesia 27
TN - Tunisia 25
EG - Egitto 24
JO - Giordania 24
PY - Paraguay 24
CZ - Repubblica Ceca 23
BO - Bolivia 21
LT - Lituania 21
AE - Emirati Arabi Uniti 20
EU - Europa 20
IL - Israele 20
MU - Mauritius 20
PA - Panama 19
NP - Nepal 18
ET - Etiopia 17
PE - Perù 17
UY - Uruguay 17
AZ - Azerbaigian 16
DZ - Algeria 16
KR - Corea 16
DK - Danimarca 13
LB - Libano 13
RO - Romania 13
CR - Costa Rica 11
KZ - Kazakistan 11
PT - Portogallo 11
SN - Senegal 11
OM - Oman 10
BG - Bulgaria 9
JM - Giamaica 9
PS - Palestinian Territory 9
RS - Serbia 9
CH - Svizzera 8
DO - Repubblica Dominicana 8
LV - Lettonia 8
NG - Nigeria 8
XK - ???statistics.table.value.countryCode.XK??? 8
AL - Albania 7
KG - Kirghizistan 7
KW - Kuwait 7
MD - Moldavia 7
NI - Nicaragua 7
SK - Slovacchia (Repubblica Slovacca) 7
BH - Bahrain 6
SY - Repubblica araba siriana 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AM - Armenia 5
GE - Georgia 5
GR - Grecia 5
TH - Thailandia 5
BW - Botswana 4
BY - Bielorussia 4
HN - Honduras 4
HU - Ungheria 4
LA - Repubblica Popolare Democratica del Laos 4
ML - Mali 4
NZ - Nuova Zelanda 4
QA - Qatar 4
Totale 43.338
Salva come PNG Salva come JPEG
Città #
Chandler 2.219
Dublin 2.209
Jacksonville 1.999
San Jose 1.714
Hong Kong 1.643
Nanjing 1.557
Singapore 1.414
Ashburn 1.385
Dallas 1.221
Beijing 861
Boardman 789
Nanchang 615
Princeton 515
Lauterbourg 506
Lawrence 494
Wilmington 489
Hebei 462
Shenyang 456
Changsha 412
Los Angeles 399
Ho Chi Minh City 397
Jiaxing 372
Medford 349
New York 258
Helsinki 257
Hangzhou 249
Hanoi 239
Tianjin 238
Buffalo 208
Ann Arbor 206
Council Bluffs 200
Milan 156
Redondo Beach 150
Munich 134
Moscow 133
Shanghai 128
Woodbridge 111
São Paulo 104
Santa Clara 100
Norwalk 97
Toronto 93
Orem 89
Johannesburg 82
Seattle 78
Verona 77
Pavia 72
The Dalles 70
Nuremberg 67
Tokyo 67
Chicago 64
Turku 62
Brooklyn 61
Jinan 61
San Francisco 60
Frankfurt am Main 59
Da Nang 58
Haiphong 56
Falls Church 54
Guangzhou 53
Chennai 52
Warsaw 51
Zhengzhou 49
Falkenstein 48
Mexico City 45
Montreal 45
Washington 45
Houston 44
Rome 44
Fairfield 42
Tashkent 42
Baghdad 40
Kunming 40
Stockholm 39
Atlanta 38
Des Moines 38
London 37
Ningbo 37
Rio de Janeiro 36
Belo Horizonte 34
Brussels 34
Denver 33
Taizhou 31
Boston 29
Hải Dương 29
Manchester 28
Nairobi 28
Phoenix 27
Curitiba 26
Columbus 24
Amsterdam 22
Lahore 22
Amman 21
Biên Hòa 21
Brasília 21
Poplar 21
Tappahannock 21
Vienna 21
Buenos Aires 20
Dhaka 20
Guarulhos 19
Totale 28.092
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 188
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 179
A B-cell lymphoproliferative disorder 173
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. 172
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data 170
A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation 168
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 166
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 162
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 154
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. 150
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 150
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 150
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 147
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 146
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 145
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 144
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 144
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 143
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 142
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 141
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 139
[Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons] 139
Blast phase of essential thrombocythemia: A single center study. 138
A case of persistent eosinophilia 138
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 137
Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides 136
Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation 136
Cord blood-derived hematopoietic progenitor cells: in vitro response to hematopoietic growth factors and their recruitment into the S-phase of the cell cycle. 136
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 136
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron 135
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 135
WALDENSTROM'S HYPERGLOBULINEMIC PURPURA IN HLA IDENTICAL SISTERS. 133
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 132
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 130
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 130
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 129
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 128
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 128
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 126
Classification and prognostic evaluation of myelodysplastic syndromes 126
Anemia associata ad endocrinopatie. 126
A gain-of-function mutation of JAK2 in myeloproliferative disorders 125
Cell cycle distribution of cord blood-derived haematopoietic progenitor cells and their recruitment into the S-phase of the cell cycle 124
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 124
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 123
Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia). 122
"In vitro" megakaryocytopoiesis in patients with HIV-related thrombocytopenic purpura. 122
Juvenile chronic myelogenous leukemia: in vitro characterization before and after allogeneic bone marrow transplantation 121
A chronic lymphoproliferative disorder 120
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). 119
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 119
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 118
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. 118
Intracellular calcium deposits and store operated calcium entry in CD34+ cells from patients with myelofibrosis carrying a CALR mutation 118
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 118
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 117
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 117
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 116
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure 116
A novel deletion of the L-ferritin iron-responsive element responsible for severe hereditary hyperferritinaemia-cataract syndrome. 115
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 115
Clinical significance of somatic mutation in unexplained blood cytopenia 115
Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome 114
A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. 113
Cerebrospinal fluid ferritin in human disease. 113
Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. 113
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 113
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. 112
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders 111
Clinical and biological implications of driver mutations in myelodysplastic syndromes 111
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. 110
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 110
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 110
JAK2 (V617F) mutation in healthy individuals 109
A patient-oriented approach to treatment of myelodysplastic syndromes. 109
Ittero. 108
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. 108
Hematologic passport for athletes competing in endurance sports: a feasibility study. 107
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 107
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 107
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 107
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 107
Revised international prognostic scoring system for myelodysplastic syndromes 107
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 106
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 106
Allelic imbalance in CALR somatic mutagenesis 106
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 106
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 106
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 106
Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells 106
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. 106
Relationship between clone metrics and clinical outcome in clonal cytopenia 105
USE OF A MONOCLONAL ANTIBODY AGAINST HUMAN HEART FERRITIN FOR EVALUATING ACIDIC FERRITIN CONCENTRATION IN HUMAN SERUM 105
Classification of anaemia on the basis of ferrokinetic parameters. 105
Myelodysplastic syndromes--coping with ineffective hematopoiesis. 105
A global strategy for prevention and detection of blood doping with erythropoietin and related drugs 105
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 105
Pincered red cells and hereditary spherocytosis. 104
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 104
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 104
Totale 12.525
Salva come PNG Salva come JPEG
Categoria #
all - tutte 189.999
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 189.999
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202184 0 0 0 0 0 0 0 0 0 0 0 84
2021/20222.188 32 8 65 39 101 130 40 119 120 93 340 1.101
2022/20236.356 743 374 47 520 634 706 3 403 2.629 33 164 100
2023/20242.266 253 446 95 204 219 618 65 137 15 53 60 101
2024/20255.893 156 567 173 188 109 216 239 540 1.230 224 677 1.574
2025/202614.870 1.044 1.234 1.656 1.792 1.504 761 3.040 594 1.224 1.174 573 274
Totale 43.994